# Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

> **NCT06096116** · PHASE3 · RECRUITING · sponsor: **Octapharma** · enrollment: 120 (estimated)

## Conditions studied

- Acquired Antithrombin Deficiency

## Interventions

- **DRUG:** Human plasma derived antithrombin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06096116
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-21
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06096116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06096116, "Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT06096116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*